Scoop6d
Season Extension Announced Due To Overwhelming Demand For Tickets
NZ Breast Cancer Foundation: New Breast Cancer Wonder Drug Would Be Life-Changing For NZ Women Breast Cancer Foundation NZ ...
Nasdaq14d
Merck & Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Results In Phase 2 Lung Cancer Trial
According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ifinatamab deruxtecan at a 12 mg/kg dose in pretreated patients. This dose has been ...
Business Wire15d
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd ...
Nature20d
Billion-dollar deals bolster oncology research
Daiichi Sankyo granted Merck exclusive, worldwide rights (excluding Japan) to co-develop and co-commercialize Daiichi's 3 antibody-drug conjugates (ADCs) including patritumab deruxtecan (HER3-DXd ...